A Recombinant Immunotoxin against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced Antigenicity

John E. Weldon, Laiman Xiang, Jingli Zhang, Richard Beers, Dawn A. Walker, Masanori Onda, Raffit Hassan, and Ira Pastan

Abstract

SS1P is a recombinant immunotoxin (RIT) engineered for the targeted elimination of malignant cells that express the tumor-associated antigen mesothelin. It is composed of an antimesothelin antibody variable fragment (Fv) linked to a cytotoxic fragment of *Pseudomonas* exotoxin A (PE) that includes domains II and III of native PE. The clinical use of SS1P is limited by its propensity to induce neutralizing antibodies and to cause a dose-limiting capillary leak syndrome (CLS) in patients. In this article, we describe a reengineered SS1P with improved properties that overcome these deficits. The redesign of SS1P consists of (i) removing the bulk of PE domain II (residues 251–273 and 284–394 of native PE), leaving only an 11-residue furin cleavage site, (ii) adding a Gly–Gly–Ser peptide linker after the furin cleavage site, and (iii) replacing eight highly solvent-exposed residues in the catalytic domain of PE. The new molecule, SS1-LR/GGS/8M, has cytotoxic activity comparable with SS1P on several mesothelin-expressing cell lines and remarkably improved activity on primary cells from patients with mesothelioma. In a mouse xenograft tumor model, high doses of SS1-LR/GGS/8M elicit antitumor activity superior to the activity of SS1P at its maximum-tolerated dose. In addition, SS1-LR/GGS/8M has greatly decreased ability to cause CLS in a rat model and reduced antigenicity or reactivity with antibodies to the sera of patients previously treated with SS1P. Mol Cancer Ther; 12(1); 1–10. ©2012 AACR.

Introduction

Recombinant immunotoxins (RIT) are engineered therapeutic proteins that combine an antibody fragment with a cytotoxic protein, typically derived from a bacterial or plant source. RITs are designed to serve as selective cytotoxic agents for the targeted elimination of cells with high specificity and high activity and without the secondary toxicities associated with chemotherapy. We have constructed RITs for the treatment of cancers by fusing the antibody variable fragment (Fv) of antibodies against tumor-associated cell surface antigens to a fragment of *Pseudomonas* exotoxin A (PE). RITs using a 38-kDa truncation of PE (PE38) have met with success in clinical trials, especially for the treatment of hematologic malignancies (1–4), such as drug-resistant hairy cell leukemia, in which malignant cells are readily accessible and patients can often be given many cycles of treatment before the development of neutralizing antibodies. Clinical trials to treat solid tumors (5–9) such as mesothelioma have been promising but less successful due to the early development of neutralizing antibodies and the occurrence of off-target toxicities.

To improve the outcome of treatment with PE-based RITs, we have applied our knowledge of the PE intoxication pathway to the redesign of these proteins. RITs are internalized via receptor-mediated endocytosis and traffic through the endolysosomal system to the Golgi, in which they undergo retrograde transport to the endoplasmic reticulum. During this trafficking stage, the toxin is activated through reduction of a disulfide bond and cleavage by the protease furin at a site that separates the Fv from the catalytic fragment of PE. Subsequently, the activated PE must translocate into the cytosol, in which it ADP-ribosylates and inactivates elongation factor 2, an essential component of the translation apparatus. This halts protein synthesis and eventually leads to cell death (for a review see ref. 10). Previous strategies designed to improve the cytotoxic activity of PE-based RITs include substitution of the native C-terminal residues of PE, REDLK, with the canonical endoplasmic reticulum–retention signal KDEL (11–14). This substitution is known to

Authors’ Affiliation: Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland

Note: Supplementary data for this article are available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/).

Current Address for John E. Weldon: Department of Biological Sciences, Towson University, Towson, MD.

Corresponding Author: Ira Pastan, Laboratory of Molecular Biology, National Cancer Institute, 37 Convent Drive, Room 5106, Bethesda, MD 20892. Phone: 301-496-4797; Fax: 301-402-1344; E-mail: pastani@mail.nih.gov

doi: 10.1158/1535-7163.MCT-12-0336
©2012 American Association for Cancer Research.
enhance the cytotoxicity of PE, presumably by improving the efficiency of retrograde transport to the endoplasmic reticulum from the Golgi but can increase off-target toxicity in animal models. Another strategy is to enhance the productive internalization of the RIT-receptor complex, and thereby increase the amount of toxin in the cell by improving the affinity between the Fv and its target (15, 16).

More recently, we have generated a protease-resistant RIT designed to withstand degradation in the endosomal system, a potential barrier to effective immunotoxin treatment (17, 18). This lysosomal degradation resistant (LR) variant RIT was produced by removing protease-sensitive regions of PE38, and targeting it to the B-cell specific CD22 receptor with the HA22 high-affinity anti-CD22 Fv (19). We found that the LR mutation did not greatly diminish in vitro activity on cell lines, but greatly reduced off-target toxicity in mice and dramatically enhanced activity on patient CLL cells in vitro. In addition, the LR variant eliminates 2 major mouse B-cell epitope groups (20) and antigen processing sites from PE38, helping to reduce its immunogenicity in mice (21).

Because of its improved properties in an HA22 background, we chose to adapt the LR variant to SS1P (Fig. 1A), a clinically relevant agent that targets the tumor-associated antigen mesothelin (22). Mesothelin is highly expressed in malignant mesotheliomas, as well as in cancers of the lung, ovary, and pancreas (23). SS1P, which contains the SS1 disulfide-stabilized antimesothelin Fv, is currently undergoing clinical trials for the treatment of mesothelioma (clinicaltrials.gov identifiers NCT01362790 and NCT01445392). Because of the modular nature of RITs, the LR variant of PE should, in principle, be applicable to targeting other tumor-associated antigens by exchanging one Fv for another. The different receptor-mediated pathways by which proteins enter cells, however, are complex and can influence RIT trafficking. CD22, the target of HA22, is expressed exclusively on B cells and associated malignancies, and is a large transmembrane glycoprotein that seems to undergo constitutive clathrin-dependent endocytic recycling (24). In contrast to CD22, mesothelin, the target of SS1P, is a glycoposphatidylinositol (GPI)-linked protein expressed on epithelial cells. GPI-linked proteins are anchored to the extracellular side of cell membranes by their C-termini, and thus must be internalized and sorted independent of cytosolic interactions (see ref. 25 for a review). Differences in receptor endocytosis and trafficking could lead to different routes of internalization, and thereby influence the cytotoxic outcome. In addition to the receptor, it is also possible that removing or adding sequences to a RIT could alter its trafficking, processing, and cytotoxic activity.

In this article, we describe the development and properties of a reengineered antimesothelin RIT, SS1-LR/GGS/8M (Fig. 1B and C). SS1-LR/GGS/8M has improved activity on primary cells from patients with mesothelioma, greatly decreased capacity to initiate capillary leak syndrome (CLS) in a rat model, and reduced antigenicity, or reactivity with antibodies in antisera from patients who had previously developed neutralizing antibodies against SS1P. On the basis of these findings SS1-LR/GGS/8M is an excellent candidate for further clinical development.

Materials and Methods

Proteins
SS1P (SS1(dsFv)-PE38) and its derivatives were expressed, refolded, and purified as described (26). SS1P was manufactured by Advanced BioScience Laboratories, Inc. All other RITs were prepared in the Laboratory of...
Molecular Biology, National Cancer Institute (NCI; Bethesda, MD). Mutations were generated using Quik-change site-directed mutagenesis (Stratagene) with primers from Lofstrand Labs Limited. Supplementary Fig. S1 shows an SDS-PAGE analysis of the purified proteins.

**Cell lines**

Several mesothelin-positive human cell lines were used in this study. The L55 lung adenocarcinoma and M30 mesothelioma cell lines were provided by Steven Albeida (University of Pennsylvania, Philadelphia, PA). The HAY mesothelioma cell line was provided by the Stehlin Foundation for Cancer Research (Houston, TX). The OVCAR-8 and A1847 ovarian cancer cell lines were provided by Hisataka Kobayashi and Stuart Aaronson (NCI, Bethesda, MD), respectively. The NCI-H322M lung adenocarcinoma cell line was obtained from the Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis Tumor Repository (NCI, Frederick, MD). The cell lines A431/K5 (27) and A431/H9 (28) are derivatives of the A431 epidermoid carcinoma cell line that have been stably transfected with vectors for human mesothelin, and grown in media supplemented with 750 μg/mL G-418 (Geneticin) for selection. All cell lines were grown at 37°C with 5% CO₂ in media supplemented with 10% FBS, 2 mM L-glutamine, 100 U penicillin, and 100 μg streptomycin (Invitrogen Corporation). A431/K5 was grown in Dulbecco’s modified Eagle’s medium; all other cell lines were grown in RPMI-1640 medium supplemented 1 mM sodium pyruvate (Invitrogen). Cells (2,000 cells/well) were plated in 96-well plates, left overnight to adhere, and incubated with varying concentrations of RITs for 72 hours at a final volume of 0.2 mL. At the end of the incubation period, 10 mRITs for 72 hours at a final volume of 0.2 mL. At the end of the incubation period, 10

Viability of cell lines treated with immunotoxins was measured using the Cell Counting Kit-8 WST-8 assay (Dojindo Molecular Technologies, Inc.). Cells (2,000 cells/well) were plated in 96-well plates, left overnight to adhere, and incubated with varying concentrations of RITs for 72 hours at a final volume of 0.2 mL. At the end of the incubation period, 10 μL of the CCK-8 reagent was added to each well and the plates were incubated at 37°C until the wells with the maximum absorbance at 450 nm reached values of approximately 1 optical density (OD). Values were normalized between controls of the CCK-8 reagent that reduced cell viability to the 50% level (EC₅₀).

Primary mesothelioma cell cultures were established as described (29) from the peritoneal or pleural fluid of 4 patients with advanced mesothelioma who were being treated on protocols approved by NCI Institutional Review Board. The resulting cells (NCI-M-02, NCI-M-03, NCI-M-16, and NCI-M-19) were judged by a pathologist to be malignant and subsequently determined to be a single population of mesothelin-expressing cells by flow cytometry. Responses to SS1P and SS1-LR/GGS/8M were evaluated at an early passage using a crystal violet assay. D-PBS and 10 ng/mL HB21 (antitransferrin receptor/PE40) were used as negative and positive controls for cell death, respectively. Each condition was evaluated in triplicate. Statistical analysis of the resulting data by ANOVA was conducted using GraphPad Prism software.

**Mouse A431/H9 xenograft antitumor assay**

Female nude mice were injected subcutaneously in the flank with 1.8 × 10⁶ A431/H9 cells in 0.2 mL RPMI with 4 mg/mL Matrigel (BD Biosciences) on day 0. Tumor volume was followed by regular caliper measurements. When tumors reached an average size of approximately 110 mm³, mice were divided into groups and intravenously injected 3 times on days 7, 9, and 12 with 0.2-mL of vehicle (0.2% HSA in D-PBS; n = 5) or vehicle containing either SS1P (0.4 mg/kg; n = 4) or SS1-LR/GGS/8M (2.5 or 5.0 mg/kg; n = 6). Follow-up experiments used the same protocol with 6 doses of 5.0 mg/kg SS1-LR/GGS/8M administered on days 6, 8, 10, 13, 15, and 17 (n = 10), and 5 doses of 10.0 mg/kg SS1-LR/GGS/8M administered on days 6, 8, 10, 17, and 20 (n = 8). This experiment and all subsequent animal experiments were handled according to the NIH guidelines approved by the Animal Care and Use Committee of the NCI.

**Mouse serum pharmacokinetics**

Groups of 9 female nude mice were injected intravenously with 10 μg of SS1P or SS1-LR/GGS/8M in 0.2 mL of 0.2% HSA in D-PBS. Subgroups of 3 mice were bled at time intervals of 2 and 20, 5 and 30, or 10 and 60 minutes. Sera were analyzed by ELISA as previously described (30).

**Rat capillary leak assay**

A previously described rat model of RIT-induced CLS (31) was used to evaluate the off-target toxicity of SS1-LR/GGS/8M. Briefly, 6- to 8-week-old female Furt hand Rowett, nu/nu (athymic) rats (Harlan-Sprague-Dawley) were injected intravenously with D-PBS, SS1P (0.2 or 0.3 mg/kg), or SS1-LR/GGS/8M (6 or 12 mg/kg). After 24 hours, the rats were euthanized and hydrothorax fluid was collected from the animals. The lungs from several rats were removed, fixed for 3 days in 10% formalin, sectioned, and stained.

**Antigenicity assay**

Binding of SS1P or SS1-LR/GGS/8M to antibodies in patient sera was analyzed essentially as described (32), except that CD22-rFc and HA22 were used for the detection of PE-specific antibodies by ELISA. Human sera were obtained under protocols 01-C-0011, 03-C-0243, and 08-C-0026.
Results and Discussion

SS1-LR

The immunotoxin SS1P (Fig. 1A) is composed of the disulfide-stabilized 2-chain antimesothelin SS1 Fv joined to PE38 (27, 33, 34). It has high cytotoxic activity on many cancer cell lines that express mesothelin, and has shown partial responses in clinical trials (5–7). The therapeutic potential of SS1P, however, is limited by its immunogenicity and its off-target toxicity. A recently designed variant of PE38, called LR (19; PE Δ251–273 and Δ285–394), has produced lower immunogenicity and off-target toxicity in mice, and could potentially alleviate these deficits in SS1P. We generated SS1-LR (Fig. 1B and C) by replacing the Fv of HA22-LR (19) with the SS1 Fv, and tested it against a panel of 8 cell lines that express mesothelin (Fig. 2). Unexpectedly, SS1-LR was considerably less active than SS1P. One of the mesothelioma cell lines, HAY, showed enhanced sensitivity to SS1-LR, but all of the other cell lines were more resistant. The ovarian cancer cell lines A1847 and OVCAR-8 were particularly resistant to SS1-LR. A complete assessment of the EC50 values can be found in Supplementary Table S1, and representative individual cytotoxicity assays are shown in Supplementary Fig. S2.

In native PE and PE38 RITs, the furin cleavage site is presented in a fixed orientation on a highly solvent exposed loop that is stabilized by a disulfide bond (Fig. 1A; ref. 35). Presumably, this conformation enhances the accessibility of the furin site for efficient cleavage by the membrane-bound furin protease. In contrast, the furin cleavage site of SS1-LR is a short tether between 2 larger protein domains, the SS1 Fv and the catalytic domain of PE, which could limit the conformational accessibility of the furin site. This does not seem to be a problem for HA22-LR internalized through CD22, but the internalization pathway of SS1-LR through mesothelin, which does not follow the typical clathrin-dependent mechanism (25), might restrict access to furin. Furin is a transmembrane protein with an extracellular/lumenal protease domain that follows a cell surface to Golgi recycling pathway (36). Both steric accessibility and the trafficking pathway could limit the essential furin cleavage step and reduce the cytotoxicity of SS1-LR.

SS1-LR/GGS

We designed several mutants to explore whether improving the accessibility of the furin cleavage site could enhance the activity of SS1-LR. Our strategy was to increase the length and flexibility of the furin site by the addition of Gly–Gly–Ser linkers. The RIT SS1-LR/GGS (Fig. 1B and C) includes a Gly–Gly–Ser linker on the C-terminal end of the 11-residue furin cleavage site, and has enhanced activity relative to SS1-LR on all cell lines tested (Fig. 2 and Supplementary Table S1). Sample cytotoxicity curves are included in Supplementary Fig. S2. Neither increasing the length of the linker (SS1-LR/GGSx2; Fig. 1B and C) nor duplication of the furin cleavage site with additional linker regions (SS1-LR/2xFur; Fig. 1B and C) enhanced the cytotoxicity beyond that of SS1-LR/GGS (data not shown). Thus, by appending a flexible linker to the SS1-LR furin site, we produced a more active RIT.

To confirm the importance of furin cleavage in the intoxication process, we also prepared the mutant SS1-LR/GGS R279G (Fig. 1B and C), which includes a point mutation of Arg to Gly at the site of hydrolysis that prevents furin cleavage. This mutant showed greatly reduced activity on the 6 cell lines tested, with negligible effect at concentrations up to 1 µg/mL (Supplementary Figure 2.

Figure 2. Relative cytotoxicity in vitro. A panel of 8 cell lines that express mesothelin was used to compare the cytotoxicities of SS1P, SS1-LR, SS1-LR/GGS, and SS1-LR/GGS/8M. For each cell line, the average EC50 of each RIT relative to the average EC50 of SS1P is presented.
Table S1). This shows that furin cleavage is essential for the full cytotoxicity of SS1-LR/GGS. The necessity of furin cleavage in the PE intoxication pathway has recently been questioned (37), but much evidence exists that furin cleavage is an important step during the PE intoxication pathway (e.g., refs. 38–40, see ref. 10 for further discussion). In the data presented here, PE intoxication is extraordinarily inefficient without a furin-processing site. Experiments are ongoing to more fully explore the role of furin cleavage in RIT intoxication.

**SS1-LR/GGS/8M**

Immunogeneity is a particular problem for SS1P in the treatment of patients with intact immune systems (discussed further in ref. 10). Previous research has identified 8-point mutations in domain III (D406A, R432G, R467A, R490A, R513A, E548S, Q592A, and K590S) that silence B-cell epitopes and dramatically reduce the immunogenicity of PE38 RITs in mice (32). We engineered SS1-LR/GGS to include these mutations, generating a new variant called SS1-LR/GGS/8M, and tested it against our panel of mesothelin-expressing cell lines (Fig. 2). The EC₅₀ values from these experiments are reported in Supplementary Table S1. SS1-LR/GGS/8M retains similar activity to SS1P on mesothelioma and lung cancer cell lines and in A431 cells transfected with mesothelin. Compared with SS1P and SS1-LR/GGS, however, the 2 ovarian cancer cell lines were particularly insensitive to SS1-LR/GGS/8M.

**Off-target toxicity**

RIT off-target toxicity in mice is the result of liver damage, which seems to be caused by sequences in domain II that are absent in LR variant RITs (19, 41). The maximum safe dose of SS1P that can be administered to mice at 3 doses every other day is 0.4 mg/kg. Higher doses cause weight loss and death (Pastan and Xiang, unpublished data). RITs engineered to include the LR variant of PE, however, show greatly reduced off-target toxicity in mice (19). We have administered SS1-LR/GGS/8M to mice in doses up to 10 mg/kg at 3 doses every other day without toxicity (data not shown).

In patients, RITs do not generally produce liver damage. Instead, they may damage capillaries, leading to CLS. This can be a major clinical management problem, because of the constellation of weight gain, edema, and hypotension (for a review of CLS, see ref. 42). It seems likely that the initial peak concentrations of PE-based RITs in the bloodstream can nonspecifically damage the endothelial cells lining the blood vessels (43).

Siegall and colleagues have described a rat model of CLS in which PE induces hydrothorax in rats as a result of damage to the lungs and lung capillaries (31, 44). Because the absence of domain II in LR-based RITs significantly decreases liver toxicity in mice, we reasoned that it might also diminish lung damage in rats. Using the rat CLS model, we administered a single intravenous injection of D-PBS, SS1P, or SS1-LR/GGS/8M and observed the rats for signs of hydrothorax (Fig. 3). Rats intravenously treated with 2 mg/kg SS1P seemed ill after 24 hours, with labored breathing and fluid accumulation in their thoracic cavity. Increasing the dose of SS1P to 3 mg/kg increased the volume of thoracic fluid. In contrast, rats treated with either D-PBS or SS1-LR/GGS/8M (6 and 12 mg/kg) showed no signs of illness and had no fluid in their chest cavity. Lungs from rats treated with D-PBS, SS1P, and SS1-LR/GGS/8M were fixed, sectioned, and stained; those from rats treated with D-PBS or SS1-LR/GGS/8M seemed normal, whereas those from rats treated with SS1P showed signs of toxicity including thickening of the vessels and fluid accumulation in the perivascular spaces (Fig. 3B). We have not yet tested higher doses to determine the precise magnitude of the effect, but there is at least a 6-fold difference in toxicity between SS1P and SS1-LR/GGS/8M using this model. No LR-based RIT has been tested clinically, but this observation strengthens the proposition that the LR-based RITs will have decreased off-target toxicity in patients.

**Mouse A431/H9 tumor model**

We evaluated the efficacy of SS1-LR/GGS/8M *in vivo* with a mouse xenograft tumor model using the A431/H9 cell line (Fig. 4). Groups of nude mice (n = 6) with tumors averaging 100 to 110 mm³ were treated intravenously on days 7, 9, and 12 with SS1-LR/GGS/8M at doses of 2.5 and
5.0 mg/kg. For comparison, additional groups were treated intravenously on the same schedule with vehicle (0.2% HSA in D-PBS; n = 5) or 0.4 mg/kg SSIP (n = 4), the maximum-tolerated dose of SSIP under this dosing schedule. The tumor size of each mouse was measured regularly for 22 days postimplantation (Fig. 4A–D).

The tumors of vehicle-treated mice grew to an average size exceeding 400 mm³ by day 12 postimplantation. The tumors of mice treated with 0.4 mg/kg SSIP showed a brief delay in growth and did not exceed 400 mm³ in size until past day 16 postimplantation. Because SS1-LR/GGS/8M can be given to mice at high doses without ill effect, we treated mice with 2.5 and 5.0 mg/kg. At a dose of 2.5 mg/kg SS1-LR/GGS/8M, the antitumor effect was slightly better than that of SSIP, but mice receiving a 5.0 mg/kg dose of SS1-LR/GGS/8M showed excellent tumor regression. Tumors reached a minimum average size of approximately 29 mm³ on day 13, but subsequently resumed growth over the remaining duration of the experiment. Tumors from 6 of 7 mice resumed growth before the end of the dose series. In the final group, 5 of 8 mice given 5 doses of 10 mg/kg SS1-LR/GGS/8M had complete and lasting responses. These mice showed undetectable tumors by day 15 postimplantation, after an initial 3 doses on days 6, 8, and 10, and tumor growth did not resume through day 31. The remaining 3 mice exhibited initial tumor regressions that reached a minimum average size of approximately 20 mm³ on day 13, but did not respond completely. By day 20, tumors from all 3 of these mice had resumed growth. Additional doses on days 17 and 20 failed to achieve any significant decrease in tumor size. We are currently evaluating tumors from these mice to determine the mechanism of resistance.

Pharmacokinetics

Previous work comparing the half-life of an LR-based RIT to a PE38-based RIT in mice showed that LR had a nearly 2-fold shorter half-life in serum than PE38 (7.8 vs. 14.6 minutes, respectively; 18). The shorter half-life negatively impacts antitumor activity in vivo by more rapidly removing the smaller RIT from circulation before it can bind to tumor cells and be internalized. We postulated that this difference was due to increased renal filtration of the smaller molecule, because size is a major determinant of renal filtration (45). Previous studies have shown that the kidney is a major route of the removal of RITs from circulation, probably by glomerular filtration and subsequent metabolism by renal tubular enzymes (46, 47).

We anticipated a difference in half-life between SSIP (63 kDa) and SS1-LR/GGS/8M (50 kDa). SSIP has a molecular weight approaching those of hemoglobin (68 kDa) and serum albumin (69 kDa), proteins that exceed the threshold for glomerular filtration and are poorly filtered from the bloodstream by the kidneys (48). SS1-LR/GGS/8M, however, is significantly smaller and thus more likely to be filtered out of circulation. We treated nude mice intravenously with 10 μg SSIP or SS1-LR/GGS/8M, and analyzed serum samples taken at several time points for the presence of RIT. Mice treated with SS1-LR/GGS/8M showed a half-life of 13 minutes in serum, compared with a half-life of 19 minutes for SSIP.

![Figure 4. Antitumor activity of SS1-LR/GGS/8M. Nude mice with A431/H9 xenograft tumors were grouped and treated intravenously with SS1-LR/GGS/8M. Initial treatment groups consisted of vehicle (n = 5; A), 0.4 mg/kg SSIP (n = 4; B), 2.5 mg/kg SS1-LR/GGS/8M (n = 6; C), and 5.0 mg/kg SS1-LR/GGS/8M (n = 6; D). Tumor size was measured over the course of 22 days. Experiments were subsequently repeated to evaluate the effect of using a greater number of doses and higher dose levels. These treatment groups consisted of 5.0 mg/kg SS1-LR/GGS/8M (n = 6; E) and 10.0 mg/kg SS1-LR/GGS/8M (n = 8; F). Tumor size was measured over the course of 31 days. All graphs indicate the tumor sizes of individual mice. Arrowheads indicate days when treatment was administered.](mct.aacrjournals.org)
The half-life of SS1P in patients is much longer, nearly 8 hours at the maximum-tolerated dose (5), but we suspect that the relative half-lives of SS1P and SS1-LR/GGS/8M will be similar between mice and patients.

We have begun work on a strategy to increase the size of SS1-LR/GGS/8M, which may restore a longer half-life. SS1P and SS1-LR/GGS/8M are targeted to mesothelin using the Fv portion of the SS1 antibody, but we have previously reported that RITs constructed with the larger Fab portion of antibodies are also highly active in cell culture (49). We plan to prepare and test SS1 Fab fusions with PE-LR/GGS/8M (73 kDa) to evaluate the proposition that increasing its size will increase the half-life of the molecule. It is possible that these larger molecules may have more difficulty penetrating solid tumors, but we expect them to be very active in combination with chemotherapy, which breaks down barriers to tumor penetration (50).

**Antigenicity**

On the basis of previous research, we assumed that the 8-point mutations in domain III of PE would silence B-cell epitopes, and thereby decrease the immunogenicity of SS1-LR/GGS/8M in mice (32). Because we could not evaluate immunogenicity in humans, however, we instead evaluated the antigenicity of SS1-LR/GGS/8M in human sera from patients who developed neutralizing antibodies to SS1P. Antigenicity refers to the capacity of a molecule to act as a target antigen and react with antibodies.

We obtained serum from 5 patients who had developed neutralizing antibodies in response to treatment with...
SS1P, and mixed it with dilutions of either SS1P or SS1-LR/GGS/8M to bind reactive antibodies. The remaining unbound complement of PE38-specific antibodies was measured using an ICC-ELISA. From these data, the concentrations of SS1P and SS1-LR/GGS/8M at which the ELISA signal was reduced by 50% (IC50) were determined (example curves are provided in Supplementary Fig. S4). The IC50 values correlate with the affinity of the antibody–antigen interaction (20). Figure 5 shows the IC50 values of SS1P relative to SS1-LR/GGS/8M plotted as percentages. For all patient sera, the ratios of the IC50 values of SS1P relative to SS1-LR/GGS/8M were less than 10%, indicating that the major fraction of SS1P-reactive antibodies in the sera were unreactive with SS1-LR/GGS/8M. This result is consistent with previous observations (32), and indicates that we have identified and silenced the majority of the human immunogenic epitopes in PE38-based RITs. Although SS1-LR/GGS/8M shows reduced antigenicity, an evaluation of its immunogenicity in humans will need to be determined in a clinical trial. Experiments in mice have shown that antigenicity and immunogenicity are closely tied (32), and we anticipate reduced immunogenicity in humans.

Activity on primary patient cells

Because cell line studies do not necessarily predict if new agents will be active in patients, we obtained primary cells from the pleural and peritoneal fluids of patients with mesothelioma and evaluated their sensitivity to SS1-LR/GGS/8M and SS1P after several passages in cell culture (Fig. 6). Viability was assessed 4 days after treatment using a crystal violet assay. The early-passage mesothelioma patient cells NCI-M-02, NCI-M-03, NCI-M-16, and NCI-M-19 showed clear responses to treatment with SS1P (>75% decrease in viability at the 100 ng/mL dose level). The same patient cells showed even greater sensitivity to SS1-LR/GGS/8M. A similarly increased sensitivity was observed when cells derived from patients with chronic lymphocytic leukemia were treated with HA22-LR (19). The mechanism of enhanced sensitivity is not clear, but we hypothesize that LR-based RITs are more stable inside the cell than PE38-based RITs because of decreased susceptibility to degradation.

Concluding remarks

We describe here the development of SS1-LR/GGS/8M, a new and highly active RIT against mesothelin-expressing tumor cells that is a significant improvement over the current clinical molecule, SS1P. Not only does SS1-LR/GGS/8M have high cytotoxic and antitumor activity, but it also can be given safely to rats and mice at doses much higher than SS1P because it does not produce off-target effects. SS1-LR/GGS/8M also has greatly lowered reactivity with human antisera against SS1P, suggesting that it will have decreased immunogenicity in patients. These properties make SS1-LR/GGS/8M a promising candidate for future clinical development.

Disclosure of Potential Conflicts of Interest

M. Onda has ownership interest (including patents). No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions

Conception and design: J.E. Weldon, R. Beers, I. Pastan
Development of methodology: J.E. Weldon, L. Xiang, J. Zhang, R. Beers, D.A. Walker
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): J.E. Weldon, L. Xiang, D.A. Walker, M. Onda, R. Hassan
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): J.E. Weldon, L. Xiang, J. Zhang, R. Beers, M. Onda, I. Pastan
Writing, review, and/or revision of the manuscript: J.E. Weldon, R. Beers, D.A. Walker, M. Onda, R. Hassan, I. Pastan
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): L. Xiang, J. Zhang, R. Hassan
Study supervision: I. Pastan

Acknowledgments

The authors thank David FitzGerald for helpful comments.

Grant Support

This research was supported by the Intramural Research Program of the NIH, NCI, Center for Cancer Research.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received April 6, 2012; revised October 11, 2012; accepted October 28, 2012; published OnlineFirst November 6, 2012.

References


Molecular Cancer Therapeutics

A Recombinant Immunotoxin against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced Antigenicity

John E. Weldon, Laiman Xiang, Jingli Zhang, et al.

Mol Cancer Ther Published OnlineFirst November 6, 2012.

Updated version
Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-12-0336

Supplementary Material
Access the most recent supplemental material at:
http://mct.aacrjournals.org/content/suppl/2012/11/06/1535-7163.MCT-12-0336.DC1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.